Monographie - Daunorubicin hydrochloride

Poslední aktualizace :
08/05/2024

Daunorubicin hydrochloride

Cheminė sandara

Prekinis pavadinimas

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cerubidin	Airija, Danija, Didžioji Britanija, Norvegija, Švedija
Cerubidine	Belgija, Čilė, Jungtinės Amerikos Valstijos, Kanada, Liuksemburgas, Marokas, Olandija, Prancūzija, Šveicarija, Tunisas, Turkija
D Blastin	Marokas
Daunac	Kolumbija
Daunobin	Indija
Daunoblastin	Austrija, Vokietija
Daunoblastina	Graikija, Iranas, Ispanija, Italija, Saudo Arabija, Venesuela, Vengrija
Daunocin	Indija, Malaizija, Peru
Daunogobbi	Argentina
Daunomed	Indija, Peru
Daunomycin	Indija
Daunoplus	Indija
Daunorubicin	Australija, Didžioji Britanija, Jungtinės Amerikos Valstijos, Kanada, Naujojoje Zelandijoje
Daunorubicina	Čilė, Ekvadoras, Kolumbija, Meksikas, Peru
Daunorubitec	Indija
Daunoside	Indija
Daunotec	Indija, Venesuela
Daurocina	Čilė
Epodoxo	Peru
Maxidauno	Argentina, Ekvadoras
Oncodaunotec	Kolumbija
Rubilem	Meksikas
Runabicon	Kolumbija, Meksikas
Zuleb	Meksikas

Bibliografija : Daunorubicin hydrochloride

	Tipas	Leidinys
3	Žurnalas	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Žurnalas	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Žurnalas	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Žurnalas	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
148	Žurnalas	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
150	Žurnalas	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	Žurnalas	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
169	Žurnalas	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Žurnalas	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Žurnalas	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Žurnalas	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Žurnalas	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
492	Žurnalas	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
632	Žurnalas	Beijnen JH, Rosing H, De Vries PA, Underberg WJM. Stability of anthracycline antitumour agents in infusion fluids. J Parenter Sci Technol 1985 ; 39: 220-222.
643	Žurnalas	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
686	Žurnalas	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
905	Žurnalas	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1265	Žurnalas	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1284	Žurnalas	Williams BA, Tritton TR. Photoinactivation of anthracyclines. Photochem Photobiol 1981 ; 34: 131-134.
1410	Žurnalas	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Žurnalas	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1520	Laboratorija	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Žurnalas	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1897	Žurnalas	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1982	Žurnalas	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Žurnalas	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3438	Žurnalas	Respaud R, Quenum L, Plichon C, Tournamille J.F, Gyan E, Antier D, Viaud-Massuard M.C. A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. J Pharm Biomed Anal 2013 ; 83 : 164-170.
3474	Laboratorija	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3540	Laboratorija	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3604	Laboratorija	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3668	Laboratorija	Dexamethasone - Summary of Product Characteristics Hospira 2015

Mentions Légales